We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Diagnostica Stago Acquires Dutch Thrombin Generation Company

By LabMedica International staff writers
Posted on 20 Oct 2010
Diagnostica Stago, Inc. More...
(DSI; Parsippany, NJ, USA), finalized the acquisition of Thrombinoscope, BV (Maastricht, The Netherlands). Originally developed at Maastricht University, Thrombinoscope, researches, develops, and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram (CAT) system. The CAT system is available for research-only use.

"The development potential of this new TG approach in hemostasis using the CAT system is very promising," noted Stephane Zamia, Ph.D., and CEO of DSI. "The addition of this approach to Stago's portfolio will allow our customers to measure TG in real-time and in larger, scalable studies."

Operations and research at the company will remain independent within the Stago Group, and will report directly to the company's scientific and clinical department. The Stago Group believes that by remaining independently controlled, this start-up company will continue promising creativity leading to product development, citing their recent acquisition of BioCytex (Marseille, France), a company specializing in standardized kits for flow cytometric analysis of blood cells.

TG is a universal test capable of assessing a patient's global hemostatic balance in the instance of hemorrhage or thrombosis. Few methods before this had allowed for TG standardization and calibration. Thrombinoscope introduced a patented, sample-specific calibrator that allows for error correction due to inter-subject plasma composition and color variations, as well as substrate consumption. This method is both specific and sensitive, thereby giving increased relevance to this hemostatic test in academic research centers, pharmaceutical companies, and contract research organizations.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France (Asnières sur Seine, France), a developer and manufacturer of Hemostasis products.

Related Links:

Diagnostica Stago
Thrombinoscope





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Pipette Calibration System
Artel PCS®
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.